ByteDance has completed a $290 million external fundraising round for Anew Labs, its artificial intelligence drug discovery unit, following a strategic spin-off from the parent group. The Shanghai-headquartered company reached a valuation of $1.5 billion in this inaugural outside raise, according to people familiar with the matter. The move marks a significant step in ByteDance's efforts to commercialize its AI for science capabilities through a more focused corporate structure with fresh capital available to support independent growth.
Strategic Independence for Drug Discovery
ByteDance decided to separate the AI drugmaker to support its long term development, as AI-driven drug discovery follows a different industry logic and management approach than its core internet operations. Anew Labs will operate with greater autonomy while ByteDance remains a majority shareholder with a 56 percent stake after the round, preserving strategic alignment. This structure is intended to give the unit the flexibility needed to advance pharmaceutical research, clinical development, and commercialization efforts.
Investor Support and Funding Structure
The fundraising was led by HSG, formerly known as Sequoia China, alongside IDG Capital and Hillhouse Investment, with 5Y Capital acting as a co-lead investor. Additional participants included Gaorong Ventures, Primavera Venture Partners and Boyu Capital, as well as strategic investor SBP Group and the state-backed Shanghai Future Industries Fund. The broad syndicate combines venture capital, strategic industry capital, and public sector support for Anew Labs' growth ambitions.
Investor Implications and Strategic Signals
The participation of investors with deep healthcare and technology expertise suggests confidence in Anew Labs' ability to translate machine learning models into tangible drug development programs. The presence of the state-backed Shanghai Future Industries Fund also reflects local government interest in advanced biomedical innovation and domestic life sciences capability. Together, these backers provide both financial resources and strategic networks that could accelerate partnerships, clinical progress and future growth.
Technology Platform and Early Pipeline
Anew Labs has developed structure prediction and protein design models including Protenix and PXDesign, alongside a small number of drug candidates. In April, Chris Li, who heads the biology department, presented an AI designed IL-17 inhibitor at the American Association of Immunologists meeting in Boston, highlighting one of the company's four candidates. The company operates across Shanghai, Singapore and San Jose, California, and listed 36 core team members on its website in May, reflecting a compact but highly specialized workforce.
Leadership and Cloud Infrastructure
The new company is led by Liu Kai, who previously worked in venture capital at IDG Capital and Fire Stone Investment for seven years before joining ByteDance in 2021. Approximately 50 core staff members moved to Anew Labs along with its algorithms, technology platform and pipeline assets. Volcano Engine, ByteDance's cloud division, will continue to provide the computing power required for AI driven drug research.
A New Direction for ByteDance
For ByteDance, retaining a majority stake in a drug development company with four candidates and no approved medicines is an unusual portfolio move for a social media and internet group. Still, the transaction signals growing confidence in AI enabled scientific discovery and the potential to build a specialized life sciences business under a separate management approach. The spin-off is also described as the company's first concrete step toward commercializing its AI for science efforts beyond internal research.
The $290 million round gives Anew Labs substantial capital, a $1.5 billion valuation and a broad group of investors as it pursues an independent path in AI drug discovery. ByteDance's continued 56 percent ownership preserves strategic alignment while allowing the unit to operate with the focus required for pharmaceutical innovation, regulatory engagement, and clinical validation. The transaction highlights how major technology companies are restructuring to support advanced AI applications in science and healthcare, with dedicated teams and specialized capital.
Source: Reuters